Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 6253.38
ONVO's Cash to Debt is ranked higher than
73% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. ONVO: 6253.38 )
Ranked among companies with meaningful Cash to Debt only.
ONVO' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 6253.38

Equity to Asset 0.93
ONVO's Equity to Asset is ranked higher than
96% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ONVO: 0.93 )
Ranked among companies with meaningful Equity to Asset only.
ONVO' s 10-Year Equity to Asset Range
Min: -7.39   Max: 0.96
Current: 0.93

-7.39
0.96
F-Score: 3
Z-Score: 55.89
M-Score: -4.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -6924.34
ONVO's Operating margin (%) is ranked lower than
97% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. ONVO: -6924.34 )
Ranked among companies with meaningful Operating margin (%) only.
ONVO' s 10-Year Operating margin (%) Range
Min: -5448.28   Max: -778.53
Current: -6924.34

-5448.28
-778.53
Net-margin (%) -6865.39
ONVO's Net-margin (%) is ranked lower than
97% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.43 vs. ONVO: -6865.39 )
Ranked among companies with meaningful Net-margin (%) only.
ONVO' s 10-Year Net-margin (%) Range
Min: -6820.05   Max: -3638.51
Current: -6865.39

-6820.05
-3638.51
ROE (%) -59.30
ONVO's ROE (%) is ranked lower than
81% of the 162 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. ONVO: -59.30 )
Ranked among companies with meaningful ROE (%) only.
ONVO' s 10-Year ROE (%) Range
Min: -120.28   Max: -120.28
Current: -59.3

ROA (%) -55.90
ONVO's ROA (%) is ranked lower than
81% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.19 vs. ONVO: -55.90 )
Ranked among companies with meaningful ROA (%) only.
ONVO' s 10-Year ROA (%) Range
Min: -519.94   Max: -77.23
Current: -55.9

-519.94
-77.23
ROC (Joel Greenblatt) (%) -2644.28
ONVO's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.66 vs. ONVO: -2644.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ONVO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2628.77   Max: -2610.36
Current: -2644.28

-2628.77
-2610.36
» ONVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ONVO Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
» More
Q3 2014

ONVO Guru Trades in Q3 2014

Paul Tudor Jones 30,491 sh (New)
» More
Q4 2014

ONVO Guru Trades in Q4 2014

Chase Coleman 500,000 sh (New)
Paul Tudor Jones 11,961 sh (-60.77%)
» More
Q1 2015

ONVO Guru Trades in Q1 2015

Chase Coleman Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ONVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.40
ONVO's P/B is ranked lower than
130% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. ONVO: 8.40 )
Ranked among companies with meaningful P/B only.
ONVO' s 10-Year P/B Range
Min: 5.38   Max: 61.09
Current: 8.4

5.38
61.09
P/S 901.30
ONVO's P/S is ranked lower than
144% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. ONVO: 901.30 )
Ranked among companies with meaningful P/S only.
ONVO' s 10-Year P/S Range
Min: 0   Max: 1250
Current: 901.3

0
1250
Current Ratio 13.58
ONVO's Current Ratio is ranked higher than
93% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. ONVO: 13.58 )
Ranked among companies with meaningful Current Ratio only.
ONVO' s 10-Year Current Ratio Range
Min: 0.04   Max: 34
Current: 13.58

0.04
34
Quick Ratio 13.56
ONVO's Quick Ratio is ranked higher than
93% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. ONVO: 13.56 )
Ranked among companies with meaningful Quick Ratio only.
ONVO' s 10-Year Quick Ratio Range
Min: 0.04   Max: 34
Current: 13.56

0.04
34
Days Sales Outstanding 26.13
ONVO's Days Sales Outstanding is ranked higher than
91% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. ONVO: 26.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
ONVO' s 10-Year Days Sales Outstanding Range
Min: 49.4   Max: 49.4
Current: 26.13

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.40
ONVO's Price/Net Cash is ranked lower than
60% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ONVO: 8.40 )
Ranked among companies with meaningful Price/Net Cash only.
ONVO' s 10-Year Price/Net Cash Range
Min: 8.74   Max: 47.25
Current: 8.4

8.74
47.25
Price/Net Current Asset Value 8.30
ONVO's Price/Net Current Asset Value is ranked lower than
66% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ONVO: 8.30 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ONVO' s 10-Year Price/Net Current Asset Value Range
Min: 8.74   Max: 42
Current: 8.3

8.74
42
Price/Tangible Book 8.00
ONVO's Price/Tangible Book is ranked lower than
95% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. ONVO: 8.00 )
Ranked among companies with meaningful Price/Tangible Book only.
ONVO' s 10-Year Price/Tangible Book Range
Min: 8.49   Max: 34.36
Current: 8

8.49
34.36
Earnings Yield (Greenblatt) -8.30
ONVO's Earnings Yield (Greenblatt) is ranked lower than
85% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. ONVO: -8.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
ONVO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -12.9   Max: 0
Current: -8.3

-12.9
0

Analyst Estimate

Mar15 Mar16
EPS($) -0.38 -0.44
EPS without NRI($) -0.38 -0.44

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:4OR.Germany, 0R02.UK, ONVO.Switzerland,
Organovo Holdings Inc is incorporated in Delaware on April 2007. The Company is a development-stage company. It is engaged in developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company intend to introduce a paradigm shift in the approach to the generation of three-dimensional human tissues, by utilizing its proprietary platform technology to create human tissue constructs in 3D that mimic native human tissue composition and architecture. The Company is subject to various laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, emissions and wastewater discharges, and the use and disposal of hazardous or potentially hazardous substances used in connection with research, including infectious disease agents.
» More Articles for ONVO.PK^M

Headlines

Articles On GuruFocus.com
2015 Must-Buys In Biotech Sector Feb 02 2015 
Why Organovo is A Safe Buy? Dec 18 2014 
Is Organovo A Safe Buy? Dec 08 2014 
This 3D Printing Company Is a Solid Long-Term Buy Jul 26 2014 
Why Organovo Is a Better Buy Than 3D Systems May 14 2014 
Dump 3D Systems and Buy Organovo May 09 2014 
Why Organovo Is The Only 3D Printing Company Worth Buying Apr 25 2014 

More From Other Websites
Organovo Holdings, Inc. To Present at Jeffries 2015 Healthcare Conference May 26 2015
Organovo Holdings, Inc. To Present at Jeffries 2015 Healthcare Conference May 26 2015
Procter & Gamble puts skin in 3D bioprinting game May 25 2015
L'Oreal USA Announces Research Partnership with Organovo to Develop 3-D Bioprinted Skin Tissue May 05 2015
L'Oreal USA Announces Research Partnership with Organovo to Develop 3-D Bioprinted Skin Tissue May 05 2015
Shires Earnings Just Made The Best Drug Reformulation Story Even Better May 01 2015
Organovo's Shareholders Get a Reality Check Apr 24 2015
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure Apr 22 2015
Organovo Holdings, Inc. Pre-Announces Preliminary Fiscal 2015 Fourth Quarter And Year End Financial... Apr 21 2015
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 21 2015
Organovo Holdings, Inc. Pre-Announces Preliminary Fiscal 2015 Fourth Quarter And Year End Financial... Apr 21 2015
Organovo Holdings (ONVO) Stock Surges Today on Cantor Fitzgerald Coverage Initiation Apr 08 2015
Three Small Cap Stocks That Are Being Overlooked By Wall Street Apr 08 2015
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Apr 07 2015
Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue Apr 01 2015
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Apr 01 2015
Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue Apr 01 2015
EXCLUSIVE: Organovo CEO Keith Murphy Talks Pipeline, Market Misconceptions Mar 22 2015
ORGANOVO HOLDINGS, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers Mar 19 2015
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK